Endometrioid

Epithelial ovarian tumors are composed of cells that cover the surface of the ovary, such as serous, mucinous, endometrioid, clear cell, and poorly differentiated adenocarcinomas. 

Blechschmidt K, Kremmer E, Hollweck R, et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn. Mol. Pathol. 2007 16 222-228. 

Gastrointestinal, pancreas, biliary, lung, transitional cell, sweat glands, mucosal squamous cell, mucinous carcinomas of female GU tract, medullary carcinoma of thyroid Breast, squamous cell, endometrioid, Brenner tumor Renal cell, hepatocellular, prostate, follicular thyroid, adrenal cortical, serous carcinomas of female GU tract, embryonal, yolk sac, mesothelioma... 

One can also recognize some correlations between the subtype of tumor and the type of hormonal exposure. Unopposed hyperestrogenism is most likely to be associated with the endometrioid type of endometrial carcinoma, rather than with clear-cell, serous-papillary, and mucinous carcinomas. 

While the risk that hormone replacement therapy may cause endometrial tumors has been widely discussed, less attention has been given to the possibility that it could increase the risk of epithelial ovarian cancer. Since cancer of the ovary has some risk factors in common with endometrial cancer (notably low parity and obesity), this possible risk needs to be considered, especially in view of the fact that the endometrioid epithelial type of ovarian tumor is histologically so similar to adenocarcinoma of the endometrium. 

Moreno-Bueno G, Sanchez-Estevez C, Cassia Ret al. Diflerential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003 63(18) 5697-5702. 

Vimentin coexpression is especially useful in differentiating endometrial endometrioid carcinomas in uterine curettage specimens from endocervical adenocarcinomas including the endometrioid variant of endocervical adenocarcinoma. Endometrial endometrioid carcinomas immunostain strongly for vimentin, but endocervical carcinomas rarely stain (weak focal staining in up to 13% of endocervical carcinomas). i > i However, with the current antigen retrieval techniques, moderate to occasionally strong vimentin expression may be seen in endocervical carcinomas, and a panel approach is more useful in this distinction. ... 

Mammaglobin expression in endometrioid carcinomas could be useful diagnostically. 

A prior study has reported uterine cervical adenocarcinomas with intestinal features to be negative for both CDX2 and CK20, but a few recent studies have shown nuclear CDX2 immunoreactivity in up to 30% of cervical adenocarcinomas. This immunoreactivity is seen not only with rniillerian mucinous or intestinal mucinous differentiation but also in endometrioid tumors of the uterine cervix. However, dominant CK7 reactivity is useful in determining gynecologic origin. 

Endometrioid adenocarcinomas of the ovary and the uterus are CDX2-I- in up to 25% of cases. 

Other PAX2 positive carcinomas gynecologic tumors (serous, clear cell and endometrioid types), but breast and transitional cell carcinomas negative... 

Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol. 1996 27 172-177. 

Jones MW, Onisko A, Dabbs DJ, et al. The value of immuno-histochemistry in distinction between endocetvical adenocat-cinoma and adenocarcinoma of endometrium, endometrioid type. A comparative tissue microattay study of 76 cases. In-tetnational Academy of Pathology. 2008 XXVII Intetnational Congtess Abstract. 

Acs G, Pasha T, Zhang PJ. WTl is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004 23 110-118. 

Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004 44 109-115. 

Lee SS. Endometrioid adenocarcinoma of the prostate a clini-copathologic and immunohistochemical study. I Surg Oncol. 1994 55 235-238. 

Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate a clinicopathological study of 16 cases. Histopathology. 1996 29 11-19. 

Kabawat SE, Bast RC, Bhan AK, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am Clin Pathol. 1983 79 98-104. 

FIGURE 14.25 Colorectal adenocarcinoma versus mullerian endometrioid adenocarcinoma. 

Colon versus mullerian endometrioid adenocarcinoma. Antibodies CK7, CK20, CEA, CDX2, ER (Fig. 14.25). CK7 is a useful initial antibody because it is positive in greater than 95% of endometrioid adenocarcinomas and minimally reactive in colorectal adenocarcinomas. Conversely, CK20 is nonreactive in endometrioid adenocarcinomas and positive in... 

Young RH, Hart WR. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma a clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol. 1998 22 805-815. 

Bostwick DC, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol. 1985 9 595. 

Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohisto-chemical study of ten cases. Cancer. 1986 57 111. 

FIGURE 18.9 Primary endocervical adenocarcinoma may mimic primary endometriai endometrioid adenocarcinoma (A). (H E.) Monocionai CEA (B) and pi 6 (C) are diffuseiy and strongiy expressed. Estrogen receptor (D) and vimentin (E) are not expressed, aithough the stroma may be vimentin positive. Primary endometriai adenocarcinoma typicaiiy exhibits the converse pro-fiie for these four markers, aithough overiap may occur in some cases. 

There has also been recent work in defining markers that could act as a counterbalance to p53. These include antibodies against antigens associated with endometrioid differentiation ER, PRjin.ii4-ii6 p-catenin,ii 3i8... 

ER and PR expression is seen in a wide range of non-uterine tissues and in both benign and malignant tumors. Of note, ER and PR expression is moderate to strong in endometrioid carcinomas, but is not expressed or only weakly expressed in clear cell carcinomas.ER and... 

---